Higher Perceived Stress during the COVID-19 pandemic increased Menstrual Dysregulation and Menopause Symptoms

Romina Garcia de Leon[1], Alexandra Baaske[2], Arianne Y Albert[2] PhD, Amy Booth[2,6], C. Sarai Racey[2,6], Shanlea Gordon[2], Laurie W. Smith, Anna Gottschlich[2, 6], Manish Sadarangani[4,5] MD, Angela Kaida[2,3] PhD, Gina S. Ogilvie[2,6] MD, Lori A. Brotto[2,7,*] PhD, Liisa A.M. Galea[1,8,9] PhD

[1]Graduate Program in Neuroscience, University of British Columbia, Vancouver, Canada.
[2]Women's Health Research Institute, Vancouver, Canada
[3]Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
[4]Department of Pediatrics, University of British Columbia, Vancouver, Canada.
[5]Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, Canada.
[6]School of Population and Public Health, University of British Columbia, Vancouver, Canada.
[7]Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada.
[8]Department of Psychology, University of British Columbia, Vancouver, Canada.
[9] Djavad Mowafaghian Centre for Brain Health, University of British Columbia
& Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

*Correspondence can be addressed to:
Dr. Liisa Galea
Djavad Mowafaghian Centre for Brain Health
University of British Columbia
2215 Wesbrook Mall
Vancouver, BC, Canada
V6T 1Z3
liisa.galea@ubc.ca

37
Statements and Declarations
39
40 <u>Funding:</u> Funding for this project was from a Michael Smith Foundation for Health
41 Research Grant (19055) and a BC Women's Health Foundation Grant (LRZ30421) both
42 awarded to LAB and GSO. Additional support was provided by CIHR (PJT-148662)
43 awarded to LAMG.
44
45 <u>Competing Interests</u> The authors have no competing interests to declare that are
46 relevant to the content of this article.
47
<u>Ethical Approval</u> Ethical approval was received from the BC Children's and Women's
Research Ethics board (H20–01421). All methods performed as a part of this study
were in accordance with the UBC Research Ethics Board guidelines.

<u>Informed consent</u> to participate was obtained from participants.

<u>Data Availability</u> Data cannot be shared publicly because of ethical restrictions. Data are
available from the UBC Research Ethics Board (contact via cwreb@bcchr.ubc.ca) for
researchers who meet the criteria for access to confidential data.

<u>Author Contributions:</u> All authors contributed to the study conception and design.
Material preparation, data collection and analysis were performed by Arianne Albert,
Amy Booth, Shanlea Gordon, Alexandra Baaske and Romina Garcia de Leon. The first
draft of the manuscript was written by Romina Garcia de Leon, Alexandra Baaske, and
Liisa Galea and all authors commented on previous versions of the manuscript. All
authors read and approved the final manuscript.
61
62 <u>Acknowledgements</u> We thank David M. Goldfarb and Melanie Murray for their
63 contributions to this work.
64
65

Abstract

Purpose

The increased stress the globe has experienced with the COVID-19 pandemic has affected mental health, disproportionately affecting women. However, how perceived stress in the first year affected menstrual and menopausal symptoms has not yet been investigated.

Methods Residents in British Columbia, Canada, were surveyed online as part of the COVID-19 Rapid Evidence Study of a Provincial Population-Based Cohort for Gender and Sex (RESPPONSE). A subgroup (n=4171) who were assigned female sex at birth (age 25-69) and were surveyed within the first 6-12 months of the pandemic (August 2020-February 2021), prior to the widespread rollout of vaccines, were retrospectively asked if they noticed changes in their menstrual or menopausal symptoms, as well as completing validated measures of stress, depression, and anxiety.

Results We found that 27.8% reported menstrual cycle disturbances and 6.7% reported increased menopause symptoms. Those who scored higher on perceived stress, depression, and anxiety scales were more likely to have reproductive cycle disturbances. Free text responses revealed that reasons for disturbances were perceived to be related to the pandemic.

Conclusions The COVID-19 pandemic has highlighted the need to research women's health issues, such as menstruation. Our data indicates that in the first year of the pandemic, almost a third of the menstruating population reported disturbances in their cycle, which is approximately two times higher than in non-pandemic situations and four times higher than any reported changes in menopausal symptoms across that first year of the pandemic.

Keywords anxiety; depression; women; reproductive cycles; stress; COVID-19

The COVID-19 pandemic led to closures of public places, strict health

regulations, and limited social interactions. These changes, along with the uncertainty of

the pandemic, resulted in increased perceived levels of stress, depression, and anxiety

(Brotto et al., 2021; Kujawa et al., 2020). Women and gender diverse individuals

exhibited greater indices of distress, including heightened risk for mental health

disorders than men throughout the COVID-19 pandemic (Brotto et al., 2021; Connor et

al., 2020; Hunt et al., 2021).

Despite these findings, there has been minimal attention paid to the effects of

sex and gender in COVID-19 studies (Brady et al., 2021; Ciarambino et al., 2021;

Edelman et al., 2022). There has been a lack of research on the specific impact of

SARS-CoV-2 vaccines, and pandemic response on female health (Sharp et al., 2021)

which has contributed to alarming anecdotal reports of menstrual cycle irregularities

following COVID-19 vaccination on social media (Male, 2021). These reported incidents

underscored the importance of studying female cycles, which are now being closely

examined in relation to COVID-19 vaccination (Edelman et al., 2022; Lee et al., 2021;

Trogstad, 2022). However, there remains a need to examine the overall impact of the

pandemic response on female menstrual cycles.

Menstrual cycle irregularities, perimenopause, and menopausal disturbances can

be important indicators of overall physical health (Alvergne & Högqvist Tabor, 2018).

Menstrual cycle irregularity is linked to metabolic dysfunction (Souza et al., 2010) and

increased risk of cardiovascular disease (Solomon et al., 2002). Furthermore,

vasomotor menopausal symptoms are related to white matter hyperintensities and

cognitive disturbances (Thurston et al., 2016). Exposure to stress affects the

hypothalamic pituitary gonadal (HPG) axes (Viau, 2002) as higher perceived stress is

correlated with menopausal symptoms (Nosek et al., 2010; Weidner et al., 2020) and

menstrual dysregulation (Nagma et al., 2015).

Thus, it is not surprising that the COVID-19 pandemic and the associated

increase in stress has led to reports of disturbances to menstrual cycles (Phelan et al.,

2021). Premenopausal people have reported irregularities in their menstrual cycles

across different phases of the COVID-19 pandemic (Demir et al., 2021), consistent with

the literature indicating that heightened perceived stress is a predictor for menstrual

irregularities (Yamamoto et al., 2009). Prolonged stress is also associated with an

increased risk for psychiatric disorders (McEwen & Akil, 2020) and females reported

higher depressive symptoms than males during the COVID-19 pandemic (Brotto et al.,

2021; Pieh et al., 2020). Moreover, studies show that depressed mood is associated

with menstrual irregularities (Yu et al., 2017), meaning that pandemic-related stress

may be affecting mental health and menstrual irregularities simultaneously or

sequentially. Given that stress and menstrual irregularities are connected (Yamamoto et

al., 2009), and may play a role in mental health disturbances (Yu et al., 2017), it is

important to study these relationships.

Heightened stress would likely have an impact on menstrual/menopausal

irregularities, but to our knowledge no study to date has examined these irregularities in

relation to psychosocial outcomes such as perceived stress, anxiety, or depression

scores, and other factors that may play a role in perceived stress (age, number of

children) within the context of the COVID-19 pandemic. We hypothesized that females

would report an increase in the number of menstrual and menopausal symptoms during

the first year of the pandemic, and secondly that these disturbances would be

associated with stress, anxiety and depression levels.

Methods

Participant Recruitment

The Rapid Evidence Study of a Provincial Population Based COhort for GeNder and

SEx (RESPPONSE) was led by the Women's Health Research Institute in British

Columbia (BC). All participants provided informed consent prior to participation in

RESPPONSE. Ethics approval was received from The BC Children's and Women's

Research Ethics Board (H20-01421). Between mid-August 2020 and March 1, 2021,

participants were recruited (Ogilvie et al., 2021). Survey responses were collected

anonymously, with the exception of postal code. All respondents who completed the

survey were invited to enter a draw to win a $100 e-gift card.

The survey was open to residents of BC aged 25 to 69 years of all sexes and genders.

However, only participants who were assigned female sex at birth were eligible for this

particular analysis (n=5608). For analyses pertaining to menstrual changes, eligibility

was restricted to: female sex, not post-menopausal, not pregnant, first six months

postpartum, and not on hormonal suppression drugs (n=1866). In addition, we also

conducted sensitivity analyses for menstrual changes to those people under 40 to avoid

conflation with possible symptoms of perimenopause (n=810). For analyses of

menopausal symptoms, eligibility was restricted to female sex and those who

responded that they were postmenopausal (n=2305). In addition, we also conducted

sensitivity analyses for menopause status to those people over 50 (n=1978) to avoid

conflation with possible symptoms of perimenopause.

Survey Design and Measures

The survey was tested for face validity, pilot tested, and implemented using

REDCap (Research Electronic Data Capture) (Harris et al., 2009). The survey consisted

of multiple modules, with the present analysis focused on female reproductive health

questions surrounding menstrual cycle and menopause symptoms.

All survey participants that were premenopausal were asked "Since the COVID-

19 pandemic and subsequent public health measures in mid-March 2020, have you

noticed any changes to your menstrual cycle? (yes/no/not applicable due to hormonal

suppression/not applicable other)", and participants that were postmenopausal were

asked " Have you noticed any changes to your postmenopausal status since mid-March

2020? (yes/no)." Respondents who indicated changes to their menstrual cycle or

postmenopausal status were prompted to check all that applied from a list of changes

and provided with a free-text box (Survey available in Supplemental Section). All free-

text responses were coded with thematic analysis using the methods outlined in Braun

& Clarke (2006) to examine the potential variables influencing these changes. All

responses were assigned to one of two main themes: 'Non-pandemic related' and

'Pandemic control measures.' "Non-pandemic related" comments were obvious

changes to their health and reproductive system at the start of the pandemic or

preceding the pandemic. Alternatively, specific mentions of changes to their status or

cycle, without medical reason, and stated as due to the pandemic were categorized as

pandemic-related. After separating all responses into these two themes, sub-themes

were created to identify reproductive changes that occurred during the pandemic. Sub-
themes were created if one or more respondents expressed the same theme in their
free-text response.

Validated scores of general pandemic stress, anxiety, and depression were
measured (Huang et al., 2006; Löwe et al., 2008). General pandemic stress was
measured using the CoRonavIruS Health Impact Survey (CRISIS) V0.3. Participants
were asked to self-report feelings of stress on a Likert scale from one (not at all) to five
(extremely). Scores for this questionnaire range from 10–50 with higher scores
indicating greater COVID-related stress.
Anxiety scores were calculated using the Generalized Anxiety Disorder
questionnaire (GAD-7) The GAD-7 used self-reported feelings of anxiety on a Likert
scale from zero (not at all) to three (nearly everyday) with scores ranging from 0–21.
Scores above 10 suggest clinically significant levels of anxiety (Spitzer et al., 2006).
The Patient Health Questionnaire (PHQ-9) was used to measure self-reported
symptoms of depression on a Likert scale from zero (not at all) to three (nearly
everyday). Scores range from 0–27 with a score of 0–4 indicating minimal depression,
5–14 indicating mild to moderate depression and 15–27 indicating moderately severe to
severe depression (Brotto et al., 2021).
Internal consistency across data collection and Cronbach's alpha in the current
sample was very good (CRISIS: $\alpha = 0.882$; GAD-7: 0.889, PHQ: $\alpha = 0.848$).
221
Statistical Analyses
Analyses were carried out using R v.4.1.3. (Core Team, 2022). The data set was
divided into two separate groups: people with menstrual periods and those in
menopause (postmenopause) as described above and summarized the percentages of
those with any changes noted. We examined the relationship between mental health
and changes in menopause status or menstruation using mixed-effects linear
regression models with individual as random effects, and controlling for age.
Significance was assessed using likelihood-ratio tests, and interactions were removed
from the models if non-significant at $p < .05$. *Post-hoc pairwise tests were conducted to*

further explore main or interaction effects with Tukey adjusted p-values. Missing data

were excluded from analyses.

Results

Survey Participants

Demographic information (age, ethnicity, gender, number of adults or children in the

household, education, etc.) is seen in Table 1. Of the premenopausal participants,

98.4% identified as women, 0.1% identified as men and 1.5% as gender diverse. Of the

postmenopausal participants, 99% identified as women, 0.1% identified as men and

0.8% as gender diverse. Given that nearly all females also identified as women, we

have chosen to use the term women+ to refer to participants in our survey.

Changes in menstrual symptoms

Among our sample of premenopausal women+, 519 (27.8% of the sample without

suppressed cycles) reported that they had noticed changes in their menstrual cycle

since March 2020. Of these 519 respondents, 44.3% indicated that their periods were

more symptomatic (painful, more bleeding, etc.), 25.4%% indicated that their periods

were longer, 23.7%% said they were having fewer periods than before the pandemic,

21.8% noticed having more periods than normal, 15.7% said their periods had gotten

shorter, 2.3% said their periods were less symptomatic. Options were not mutually

exclusive and we received 784 answers from a potential 519 respondents. Moreover,

17.8% used free-text space to explain the changes to their menstrual cycles that they

had noticed. The analysis of the free text responses indicated that there were twice as

many respondents that indicated their changes in symptoms were due to the *Pandemic*

control measures(Table 2).

As those aged >40 years are more likely to be experiencing perimenopause, which

could create menstrual disturbances independent of psychosocial stress, we undertook

a sensitivity analysis of those who were less than 40 years old. Of this subset (n=810),

29.2% (n=237) reported changes in their menstrual cycle since the pandemic began. In

addition, 52.7% indicated that their periods were more symptomatic (painful, more

bleeding, etc.), 32.1% indicated that their periods had gotten longer, 13.1% said they

were having fewer periods than normal, 20.7% noticed having more periods than

normal, 19.0% said their periods had gotten shorter, 2.1% said their periods were less

symptomatic, and 19.8% used free-text space to explain the changes to their menstrual

cycles that they had noticed. Options were not mutually exclusive and we received 378

answers from a potential 237 respondents.

Changes in menopausal symptoms

Among our sample of postmenopausal females (n = 2305), 155 (6.7%) reported that

they noticed changes in their postmenopausal status since mid-March 2020. Of this

subset (n=155), 16.1% indicated that they started bleeding again and 12.3% indicated

that they were experiencing "more menstrual symptoms". Additionally, 72.9% used free-

text space to explain the changes to their postmenopausal status. The analysis of the

free-text responses revealed that there were four times as many respondents that

indicated changes to postmenopausal status falling into the "due to the pandemic

control measures" category (Table 3).

As those aged <50 years are more likely to be experiencing perimenopause, which

could create menopausal disturbances independent of psychosocial stress, a sensitivity

analysis that restricted to those ≥50 (n = 1978) was conducted. Of this subset, there

were 127 (6.4%) who reported that they had noticed changes in their postmenopausal

status since before the pandemic. Of this subset (n=127), 18.1% indicated that they

started bleeding again and 7.9% indicated that they were experiencing "more menstrual

symptoms". Additionally, 71.7% of this subset used free-text space to explain the

changes to their postmenopausal status that they had noticed. Analysis of these free-

text responses revealed that 19.8% of reported changes were associated with the onset

of the pandemic and 80.1% were not not pandemic-related.

Higher pandemic stress, anxiety, and depression symptoms were related to
more disturbances in menstrual and menopausal symptoms

We next examined whether any changes to menstrual or menopause symptoms were

related to anxiety, depression, or perceived stress. We found that across both groups,

more disturbances in their cycles indicated they scored higher on each of the

psychosocial measures, with premenopausal women+ scoring higher than

postmenopausal women+. For premenopausal women+ pandemic stress were 3.9

(95%CI:3.1-4.8) points higher, anxiety scores were 2.0 (95%CI: 1.6-2.4) points higher,

and depression scores were 2.4 (95%CI: 2.0-2.8) points higher on average in those that

reported menstrual cycle disturbances(Figure 1 A-C). For postmenopausal women+,

pandemic stress scores were 2.9 (95%CI: 1.9-3.9) points higher, anxiety scores were

1.5 (95%CI: 0.9-2.1) points higher, depression scores were 1.8 (95%CI: 1.2-2.5) points

higher on average in those that reported changes to their menopausal status (Figure

1D-F).

Relationship of menstrual or postmenopausal disturbances to number of children
308

As previous studies have found an association between number of children and stress

(Bigalke et al., 2020), we also examined whether the number of children influenced our

results. We ran these analyses in premenstrual women+ that were under 40, choosing

to exclude individuals who may have been perimenopausal based on age. There was

no significant relationship between the number of children and whether or not the

participant indicated they had disturbances to their menstrual cycle (p=0.100). We next

examined whether or not there was a relationship between menopausal disturbances

and the number of children. There was a significant relationship (p=0.007), however

when we used age as a covariate the effect was no longer significant (p=0.409). There

were also no significant relationships between the number of children and pandemic

stress scores, after controlling for age and changes to menstruation or menopause

(p=0.167 and 0.400, respectively).

Discussion

In a sample of 4171 surveyed women+ in BC that met our inclusion criteria,

27.8% of naturally cycling women+ had a disruption in their menstrual cycle and 6.7% of

postmenopausal women+ indicated a change in their status, across the first year of the

COVID-19 pandemic and prior to widespread rollout of COVID-19 vaccines. These

disturbances to the reproductive cycles were related to higher levels of anxiety,

depression, and perceived stress, but not to the number of children, in both pre and

postmenopausal women+. Premenopausal women+ with menstrual cycle phase

disturbances scored higher on perceived stress (3.4 points), anxiety (2.0) and

depression (2.4) measures. We previously found that women had higher levels of

perceived stress, depression, and anxiety compared to men, using data from the same

source (Brotto et al., 2021). Our findings here indicate that both pre and

postmenopausal women+ with higher levels of mental distress experienced greater

disturbances in reproductive cycles. Stress has pervasive effects on mental and

physical health and our results add to the growing data that female-specific reproductive

cycles are also affected.

During the first year of the pandemic menstrual cycle disturbances were related to

distress, anxiety and depression.

We found that in the first year of the pandemic, 27.8% of the naturally-cycling

women+ surveyed had disturbances to their menstrual cycles. This is slightly lower than

other surveys suggesting that 44% of women (including women that were younger than

our own cohort 18-24) noticed changes in their cycles using fertility tracking devices

(Buran & Gerçek Öter, 2022; Haile et al., 2022). Other studies have suggested that the

baseline rates of menstrual disturbances are ~15% (Toffel et al., 2013, Kim et al., 2018).

Premenopausal women in our study with reported menstrual disturbances had 3.4 times

higher perceived stress. Our findings are consistent with another study that showed an

association between perceived stress during the COVID-19 pandemic and menstrual

irregularities (Ozimek et al., 2022). Although the literature suggests that parental

responsibility increases perceived stress in women compared to men (Bigalke et al.,

2020)**,** we found no evidence that there was a significant relationship between the

number of children, and changes in the menstrual cycle or in perceived stress in

women+ younger than 40. Our data also indicate that anxiety scores were 2 points

higher and depression scores were 2.4 points higher on average in those that reported

menstrual cycle disturbances. As can be seen in Figure 1 this was enough of a change

to push the average depression scores to mild-moderate depression, however the

values for anxiety remain below a clinical diagnosis. Our findings add to the growing

body of research on the relationship between pandemic-related stress and menstrual

disturbances.

Increased menopause symptoms were associated with increased perceived stress,

anxiety and depression

We also found that fewer than ten percent of postmenopausal women+ noticed

changes to their menopausal status during the first year of the pandemic. Those who

noticed changes in their status reported more menopausal symptoms, and furthermore

these individuals were more likely to score higher on perceived stress, depression and

anxiety. Perimenopause is thought to be a time of heightened risk for mental health

disruption (Schmidt, 2005) and those with menopausal symptoms may be at greater risk

to develop psychiatric disorders (Cohen et al., 2006).

The percentage of disturbances in reproductive symptoms was four times greater

in our sample of premenopausal (27.8%) compared to postmenopausal women+ (6.7%)

. It is not clear why this large difference occurred but may be due to age, influence of

stress on the HPG axis, or level of stress overall. Indeed, other studies, including data

from this same sample, have found that perceived stress, anxiety and depression

scores were reduced with increasing age (Brotto et al., 2021; Tang et al., 2022). Thus,

our findings of greater premenopausal versus postmenopausal disturbances aligns with

data indicating mental health indices were lower for older adults during the first year of

the pandemic (Brotto et al., 2021). Hypothalamic-pituitary-adrenal (HPA) axis activation,

via stress, initially stimulates, and chronic activation inhibits the HPG resulting in

menstrual abnormalities (Toufexis et al., 2014) and as these interactions vary across

age (Heck & Handa, 2019; Phumsatitpong et al., 2021), this may also explain our

findings as there would have been less HPA activation in the postmenopausal women+

in our sample. However, it is also possible that the premenopausal versus

postmenopausal difference was due, in part, to the differences in the question posed to

the two different groups, as our survey asked about menopause status rather than

symptoms of menopause.

Relevance and Limitations

Allostatic load, or the cumulative burden of a variety of stressors, affects

cardiovascular and metabolic health (Guidi et al., 2021; McEwen, 1998). However, it is

important to acknowledge that female-specific factors, such as menstruation and

menopause, are also impacted by chronic stress. Others have postulated that female

health is cyclical as menstrual patterns correspond to changes in immune system

function (Alvergne & Högqvist Tabor, 2018). Moreover, there are specific interactions

between gonadal hormones and immune cells (Baker et al., 2004) emphasizing

important crosstalk (Arambula & McCarthy, 2020). It is possible that the mechanism

behind stress and menstrual changes also involves glucocorticoid receptors in the

endometrium (Michael & Papageorghiou, 2008). Although SARS-CoV-2 infection and

vaccines use can also disrupt reproductive cycles in the short term (Edelman et al.,

2022; Lee et al., 2021), we do not believe this influenced our findings because we found

that the seroprevalence of previous infection in this cohort was 2.9% (Racey et al.,

submitted) and vaccines were not widely available to the general BC population at the

time of this survey.

There are limitations to our study. This was a retrospective survey that required

online access. However, our findings of high levels of menstrual disturbances is

consistent with other studies using data from menstrual tracking apps (Haile et al.,

2022). In our survey we did not obtain information on the normal levels of menstrual or

menopausal symptoms pre-COVID19 pandemic hence we are only able to cross study

comparisons.

This survey was limited to residents of the province of BC and our unique

patterns of pandemic restriction measures may have impacted results. We also asked

about menopausal status rather than menopausal symptoms and this may have

reduced responses to this population of postmenopausal people. In our survey we also

did not clarify why people had suppressed cycles (e.g which type of hormonal

contraceptives, gender affirming hormone therapy) which future studies could explore.

We cannot rule out a selection bias in this study, and it is possible that individuals

who experienced higher stress pre- and post pandemic were more likely to participate.

Similarly, those with menstrual abnormalities may be hyper-aware of their menstrual

cycle and led them to participate in the current study.

Conclusions

The stress associated with the pandemic has impacted both our physical and mental

health and our findings suggest that this includes female-specific physical health

characteristics. It is imperative to continue advancing the literature on external and

internal factors impacting women's reproductive health. Factors that can mitigate

against the effects of stress such as social support (Zhao et al., 2019) and exercise

(Belgen Kaygısız et al., 2020), which were limited during the initial phases of the

pandemic, may have exacerbated the negative outcomes on reproductive cycles for

women+. Given the lack of attention to women's health data (Rechlin et al., 2021), more

studies examining female-specific health indices are needed in the literature.

436
437

438   References
439
440
Alvergne, A., & Högqvist Tabor, V. (2018). Is Female Health Cyclical? Evolutionary Perspectives

on Menstruation. *Trends in Ecology & Evolution*, *33*(6), 399–414.

https://doi.org/10.1016/j.tree.2018.03.006

Arambula, S. E., & McCarthy, M. M. (2020). Neuroendocrine-Immune Crosstalk Shapes Sex-

Specific Brain Development. *Endocrinology*, *161*(6), bqaa055.

https://doi.org/10.1210/endocr/bqaa055

Baker, A. E., Brautigam, V. M., & Watters, J. J. (2004). Estrogen modulates microglial

inflammatory mediator production via interactions with estrogen receptor beta.

Endocrinology, *145*(11), 5021–5032. https://doi.org/10.1210/en.2004-0619

Bigalke, J. A., Greenlund, I. M., & Carter, J. R. (2020). Sex differences in self-report anxiety and

sleep quality during COVID-19 stay-at-home orders. *Biology of Sex Differences*, *11*(1), 56.

https://doi.org/10.1186/s13293-020-00333-4

Brady, E., Nielsen, M. W., Andersen, J. P., & Oertelt-Prigione, S. (2021). Lack of consideration of

sex and gender in COVID-19 clinical studies. *Nature Communications*, *12*(1), 4015.

https://doi.org/10.1038/s41467-021-24265-8

Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. *Qualitative Research in*

Psychology, *3*(2), 77–101. https://doi.org/10.1191/1478088706qp063oa

Brotto, L. A., Chankasingh, K., Baaske, A., Albert, A., Booth, A., Kaida, A., Smith, L. W., Racey, S.,

Gottschlich, A., Murray, M. C. M., Sadarangani, M., Ogilvie, G. S., & Galea, L. (2021). *The*

influence of sex, gender, age, and ethnicity on psychosocial factors and substance use

throughout phases of the COVID-19 pandemic (p. 2021.06.08.21258572). medRxiv.

https://doi.org/10.1101/2021.06.08.21258572

Buran, G., & Gerçek Öter, E. (2022). Impact of the awareness and fear of COVID-19 on

menstrual symptoms in women: A cross-sectional study. *Health Care for Women*

International, *43*(4), 413–427. https://doi.org/10.1080/07399332.2021.2004149

Ciarambino, T., Para, O., & Giordano, M. (2021). Immune system and COVID-19 by sex

differences and age. *Women's Health (London, England)*, *17*, 17455065211022262.

https://doi.org/10.1177/17455065211022262

Cohen, L. S., Soares, C. N., Vitonis, A. F., Otto, M. W., & Harlow, B. L. (2006). Risk for New Onset

of Depression During the Menopausal Transition: The Harvard Study of Moods and

Cycles. *Archives of General Psychiatry*, *63*(4), 385–390.

https://doi.org/10.1001/archpsyc.63.4.385

Connor, J., Madhavan, S., Mokashi, M., Amanuel, H., Johnson, N. R., Pace, L. E., & Bartz, D.

(2020). Health risks and outcomes that disproportionately affect women during the

Covid-19 pandemic: A review. *Social Science & Medicine (1982)*, *266*, 113364.

https://doi.org/10.1016/j.socscimed.2020.113364

Core Team, R. (2022). *R: A language and environment for statistical computing. R Foundation*

for Statistical Computing Vienna, Austria. https://www.r-project.org/

Demir, O., Sal, H., & Comba, C. (2021). Triangle of COVID, anxiety and menstrual cycle. *Journal*

of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and

Gynaecology, *41*(8), 1257–1261. https://doi.org/10.1080/01443615.2021.1907562

Edelman, A., Boniface, E. R., Benhar, E., Han, L., Matteson, K. A., Favaro, C., Pearson, J. T., &

Darney, B. G. (2022). Association Between Menstrual Cycle Length and Coronavirus

Disease 2019 (COVID-19) Vaccination: A U.S. Cohort. *Obstetrics & Gynecology*,

10.1097/AOG.0000000000004695. https://doi.org/10.1097/AOG.0000000000004695

Guidi, J., Lucente, M., Sonino, N., & Fava, G. A. (2021). Allostatic Load and Its Impact on Health:

A Systematic Review. *Psychotherapy and Psychosomatics*, *90*(1), 11–27.

https://doi.org/10.1159/000510696

Haile, L., van de Roemer, N., Gemzell-Danielsson, K., Perelló Capó, J., Lete Lasa, I., Vannuccini,

S., Koch, M. C., Hildebrandt, T., & Calaf, J. (2022). The global pandemic and changes in

women's reproductive health: An observational study. *The European Journal of*

Contraception & Reproductive Health Care, *0*(0), 1–5.

https://doi.org/10.1080/13625187.2021.2024161

Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research

electronic data capture (REDCap)—A metadata-driven methodology and workflow

process for providing translational research informatics support. *Journal of Biomedical*

Informatics, *42*(2), 377–381. https://doi.org/10.1016/j.jbi.2008.08.010

Heck, A. L., & Handa, R. J. (2019). Sex differences in the hypothalamic-pituitary-adrenal axis'

response to stress: An important role for gonadal hormones.

Neuropsychopharmacology: Official Publication of the American College of

Neuropsychopharmacology, *44*(1), 45–58. https://doi.org/10.1038/s41386-018-0167-9

Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008). The link between

childhood trauma and depression: Insights from HPA axis studies in humans.

Psychoneuroendocrinology, *33*(6), 693–710.

https://doi.org/10.1016/j.psyneuen.2008.03.008

Huang, F. Y., Chung, H., Kroenke, K., Delucchi, K. L., & Spitzer, R. L. (2006). Using the patient

health questionnaire-9 to measure depression among racially and ethnically diverse

primary care patients. *Journal of General Internal Medicine*, *21*(6), 547–552.

Hunt, C., Gibson, G. C., Vander Horst, A., Cleveland, K. A., Wawrosch, C., Granot, M., Kuhn, T.,

Woolverton, C. J., & Hughes, J. W. (2021). Gender diverse college students exhibit higher

psychological distress than male and female peers during the novel coronavirus (COVID-

19) pandemic. *Psychology of Sexual Orientation and Gender Diversity*, *8*(2), 238–244.

https://doi.org/10.1037/sgd0000461

Kujawa, A., Green, H., Compas, B. E., Dickey, L., & Pegg, S. (2020). Exposure to COVID-19

pandemic stress: Associations with depression and anxiety in emerging adults in the

United States. *Depression and Anxiety*, *37*(12), 1280–1288.

https://doi.org/10.1002/da.23109

Lee, K. M., Junkins, E. J., Fatima, U. A., Cox, M. L., & Clancy, K. B. (2021). *Characterizing*

menstrual bleeding changes occurring after SARS-CoV-2 vaccination (p.

2021.10.11.21264863). medRxiv. https://doi.org/10.1101/2021.10.11.21264863

Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008).

Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in

the general population. *Medical Care*, 266–274.

Male, V. (2021). Menstrual changes after covid-19 vaccination. *BMJ*, *374*, n2211.

https://doi.org/10.1136/bmj.n2211

McEwen, B. S. (1998). Stress, adaptation, and disease. Allostasis and allostatic load. *Annals of*

the New York Academy of Sciences, 840, 33–44. https://doi.org/10.1111/j.1749-

6632.1998.tb09546.x

McEwen, B. S., & Akil, H. (2020). Revisiting the Stress Concept: Implications for Affective

Disorders. *Journal of Neuroscience, 40*(1), 12–21.

https://doi.org/10.1523/JNEUROSCI.0733-19.2019

Michael, A. E., & Papageorghiou, A. T. (2008). Potential significance of physiological and

pharmacological glucocorticoids in early pregnancy. *Human Reproduction Update, 14*(5),

497–517. https://doi.org/10.1093/humupd/dmn021

Montano, L. T., & Acebes, K. M. L. (2020). Covid stress predicts depression, anxiety and stress

symptoms of Filipino respondents. *International Journal of Research in Business and*

Social Science, 9(4), 78–103. https://doi.org/10.20525/ijrbs.v9i4.773

Nagma, S., Kapoor, G., Bharti, R., Batra, A., Batra, A., Aggarwal, A., & Sablok, A. (2015). To

Evaluate the Effect of Perceived Stress on Menstrual Function. *Journal of Clinical and*

Diagnostic Research : JCDR, 9(3), QC01–QC03.

https://doi.org/10.7860/JCDR/2015/6906.5611

Nosek, M., Kennedy, H. P., Beyene, Y., Taylor, D., Gilliss, C., & Lee, K. (2010). The effects of

perceived stress and attitudes toward menopause and aging on symptoms of

menopause. *Journal of Midwifery & Women's Health, 55*(4), 328–334.

https://doi.org/10.1016/j.jmwh.2009.09.005

Ogilvie, G. S., Gordon, S., Smith, L. W., Albert, A., Racey, C. S., Booth, A., Gottschlich, A.,

Goldfarb, D., Murray, M. C. M., Galea, L. A. M., Kaida, A., Brotto, L. A., & Sadarangani, M.

(2021). Intention to receive a COVID-19 vaccine: Results from a population-based survey

in Canada. *BMC Public Health*, *21*(1), 1017. https://doi.org/10.1186/s12889-021-11098-

9

Ozimek, N., Velez, K., Anvari, H., Butler, L., Goldman, K. N., & Woitowich, N. C. (2022). Impact of

stress on menstrual cyclicity during the coronavirus disease 2019 pandemic: A survey

study. *Journal of Women's Health*, *31*(1), 84–90.

Phelan, N., Behan, L. A., & Owens, L. (2021). The Impact of the COVID-19 Pandemic on

Women's Reproductive Health. *Frontiers in Endocrinology*, *12*, 642755.

https://doi.org/10.3389/fendo.2021.642755

Phumsatitpong, C., Wagenmaker, E. R., & Moenter, S. M. (2021). Neuroendocrine interactions

of the stress and reproductive axes. *Frontiers in Neuroendocrinology*, *63*, 100928.

https://doi.org/10.1016/j.yfrne.2021.100928

Pieh, C., Budimir, S., & Probst, T. (2020). The effect of age, gender, income, work, and physical

activity on mental health during coronavirus disease (COVID-19) lockdown in Austria.

Journal of Psychosomatic Research, *136*, 110186.

https://doi.org/10.1016/j.jpsychores.2020.110186

Racey, C., Booth, A., Albert, A., Smith, L., Krajden M, M. M., Côté, H., Gottschlich, A.,

Sadarangani, A., Galea, L., Kaida, A., Brotto, L., & Ogilvie, G. ((Submitted)). Seropositivity

of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: Cross-sectional

survey with dried blood spot samples. *BMJ Open*.

Rechlin, R. K., Splinter, T. F., Hodges, T. E., Albert, A. Y., & Galea, L. A. (2021). Harnessing the

power of sex differences: What a difference ten years did not make. *BioRxiv*.

Salari, N., Hosseinian-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M.,

Rasoulpoor, S., & Khaledi-Paveh, B. (2020). Prevalence of stress, anxiety, depression

among the general population during the COVID-19 pandemic: A systematic review and

meta-analysis. *Globalization and Health*, *16*(1), 57. https://doi.org/10.1186/s12992-020-

00589-w

Schmidt, P. J. (2005). Mood, depression, and reproductive hormones in the menopausal

transition. *The American Journal of Medicine*, *118*(12, Supplement 2), 54–58.

https://doi.org/10.1016/j.amjmed.2005.09.033

Sharp, G. C., Fraser, A., Sawyer, G., Kountourides, G., Easey, K. E., Ford, G., Olszewska, Z., Howe,

L. D., Lawlor, D. A., Alvergne, A., & Maybin, J. A. (2021). The COVID-19 pandemic and the

menstrual cycle: Research gaps and opportunities. *International Journal of*

Epidemiology, dyab239. https://doi.org/10.1093/ije/dyab239

Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer,

F. E., & Manson, J. E. (2002). Menstrual Cycle Irregularity and Risk for Future

Cardiovascular Disease. *The Journal of Clinical Endocrinology & Metabolism*, *87*(5),

2013–2017. https://doi.org/10.1210/jcem.87.5.8471

Souza, F. A. C., Dias, R., Fernandes, C. E., Pimentel, F., & Dias, D. (2010). Menstrual irregularity:

A possible clinical marker of metabolic dysfunction in women with class III obesity.

Gynecological Endocrinology, *26*(10), 768–772.

https://doi.org/10.3109/09513590.2010.487603

Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing

generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*, *166*(10), 1092–

1097.

Tang, Q., Wang, Y., Li, J., Luo, D., Hao, X., & Xu, J. (2022). Effect of Repeated Home Quarantine

on Anxiety, Depression, and PTSD Symptoms in a Chinese Population During the COVID-

19 Pandemic: A Cross-sectional Study. *Frontiers in Psychiatry*, *13*.

https://www.frontiersin.org/article/10.3389/fpsyt.2022.830334

Thurston, R. C., Aizenstein, H. J., Derby, C. A., Sejdić, E., & Maki, P. M. (2016). Menopausal Hot

Flashes and White Matter Hyperintensities. *Menopause (New York, N.Y.)*, *23*(1), 27–32.

https://doi.org/10.1097/GME.0000000000000481

Toufexis, D., Rivarola, M. A., Lara, H., & Viau, V. (2014). Stress and the Reproductive Axis.

Journal of Neuroendocrinology, *26*(9), 573–586. https://doi.org/10.1111/jne.12179

Trogstad, L. (2022). *Increased Occurrence of Menstrual Disturbances in 18- to 30-Year-Old*

Women after COVID-19 Vaccination (SSRN Scholarly Paper ID 3998180). Social Science

Research Network. https://doi.org/10.2139/ssrn.3998180

Viau, V. (2002). Functional Cross-Talk Between the Hypothalamic-Pituitary-Gonadal and -

Adrenal Axes. *Journal of Neuroendocrinology*, *14*(6), 506–513.

https://doi.org/10.1046/j.1365-2826.2002.00798.x

Weidner, K., Bittner, A., Beutel, M., Goeckenjan, M., Brähler, E., & Garthus-Niegel, S. (2020).

The role of stress and self-efficacy in somatic and psychological symptoms during the

climacteric period—Is there a specific association? *Maturitas*, *136*, 1–6.

https://doi.org/10.1016/j.maturitas.2020.03.004

Yamamoto, K., Okazaki, A., Sakamoto, Y., & Funatsu, M. (2009). The relationship between

premenstrual symptoms, menstrual pain, irregular menstrual cycles, and psychosocial

stress among Japanese college students. *Journal of Physiological Anthropology*, *28*(3),

129–136. https://doi.org/10.2114/jpa2.28.129

Yu, M., Han, K., & Nam, G. E. (2017). The association between mental health problems and

menstrual cycle irregularity among adolescent Korean girls. *Journal of Affective*

Disorders, *210*, 43–48. https://doi.org/10.1016/j.jad.2016.11.036

Table 1. Demographic characteristics of respondents.
621 + denotes GenderQueer, Agender, Two-Spirit, other
622

	Menstruation Changes				Postmenopausal Changes			
Age	Total	No	Yes	P-value	Total	No	Yes	P-value
	No. 1,866	No. 1,347	No. 519		No. 2,305	No. 2,150	No. 155	
25-29	183 (9.8%)	**127 (9.4%)**	56 (10.8%)	0.14	5 (0.2%)	4 (0.2%)	1 (0.6%)	< 0.0001
30-39	627 (33.6%)	446 (33.1%)	181 (34.9%)		38 (1.6%)	34 (1.6%)	4 (2.6%)	
40-49	808 (43.3%)	602 (44.7%)	206 (39.7%)		174 (7.5%)	151 (7.0%)	23 (14.8%)	
50-59	242 (13.0%)	166 (12.3%)	76 (14.6%)		948 (41.1%)	854 (39.7%)	94 (60.6%)	
60-69	6 (0.3%)	6 (0.4%)	0 (0.0%)		1,140 (49.5%)	1,107 (51.5%)	33 (21.3%)	
Gender								
Woman	1,837 (98.4%)	1,333 (99.0%)	504 (97.1%)	0.006	2,283 (99.0%)	2,130 (99.1%)	153 (98.7%)	0.49
Man	1 (0.1%)	1 (0.1%)	0 (0.0%)		3 (0.1%)	3 (0.1%)	0 (0.0%)	
Non-Binary, GenderQueer, Agender, Two-spirit or other	28 (1.5%)	13 (1.0%)	15 (2.9%)		19 (0.8%)	17 (0.8%)	2 (1.3%)	
Indigenous								
Indigenous	72 (3.9%)	47 (3.5%)	25 (4.8%)	0.35	52 (2.3%)	47 (2.2%)	5 (3.2%)	0.047
Not Indigenous	1,706 (91.4%)	1,235 (91.7%)	471 (90.8%)		2,147 (93.1%)	2,008 (93.4%)	139 (89.7%)	
Prefer not to answer	19 (1.0%)	15 (1.1%)	4 (0.8%)		13 (0.6%)	10 (0.5%)	3 (1.9%)	
Missing	69 (3.7%)	50 (3.7%)	19 (3.7%)		93 (4.0%)	85 (4.0%)	8 (5.2%)	
Latin American								
Latin American	40 (2.1%)	25 (1.9%)	15 (2.9%)	0.21	21 (0.9%)	18 (0.8%)	3 (1.9%)	0.16
Not	1,819 (97.5%)	1,316 (97.7%)	503 (96.9%)		2,267 (98.4%)	2,118 (98.5%)	149 (96.1%)	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)			14 (0.7%)	3 (1.9%)	

					17 (0.7%)			
South Asian								
Not	1,800 (96.5%)	1,295 (96.1%)	505 (97.3%)	0.38	2,258 (98.0%)	2,112 (98.2%	146 (94.2%	0.012
South Asian	59 (3.2%)	46 (3.4%)	13 (2.5%)		30 (1.3%)	24 (1.1%)	6 (3.9%)	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
Black								
Black	19 (1.0%)	15 (1.1%)	4 (0.8%)	0.61	8 (0.3%)	8 (0.4%)	0 (0.0%)	1
Not Black	1,840 (98.6%)	1,326 (98.4%)	514 (99.0%)		2,280 (98.9%)	2,128 (99.0%)	152 (98.1%	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
White								
Non-White	368 (19.7%)	281 (20.9%)	87 (16.8%)	0.044	245 (10.6%)	222 (10.3%)	23 (14.8%	0.077
White	1,491 (79.9%)	1,060 (78.7%)	431 (83.0%)		2,043 (88.6%)	1,914 (89.0%	129 (83.2%	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
Education								
More than high school	1,705 (91.4%)	1,232 (91.5%)	473 (91.1%)	0.93	1,924 (83.5%)	1,788 (83.2%	136 (87.7%	0.18
High school or less	159 (8.5%)	114 (8.5%)	45 (8.7%)		377 (16.4%)	358 (16.7%)	19 (12.3%)	
Missing	2 (0.1%)	1 (0.1%)	1 (0.2%)		4 (0.2%)	4 (0.2%)	0 (0.0%)	
Number of Adults in Household								
One	388 (20.8%)	273 (20.3%)	115 (22.2%)	0.65	649 (28.2%)	601 (28.0%)	48 (31.0%)	0.51
Three or more	364 (19.5%)	263 (19.5%)	101 (19.5%)		526 (22.8%)	488 (22.7%)	38 (24.5%)	
Two	1,113 (59.6%)	810 (60.1%)	303 (58.4%)		1,121 (48.6%)	1,052 (48.9%	69 (44.5%)	
Missing	1 (0.1%)	1 (0.1%)	0 (0.0%)		9 (0.4%)	9 (0.4%)	0 (0.0%)	
Children < 5								
None	1,514 (81.1%)	1,079 (80.1%)	435 (83.8%)	0.095	2,225 (96.5%)	2,076 (96.6%	149 (96.1%	0.39
One	239 (12.8%)	185 (13.7%)	54 (10.4%)		23 (1.0%)	22 (1.0%)	1 (0.6%)	

Two or more	70 (3.8%)	54 (4.0%)	16 (3.1%)		14 (0.6%)	12 (0.6%)	2 (1.3%)	
Missing	43 (2.3%)	29 (2.2%)	14 (2.7%)		43 (1.9%)	40 (1.9%)	3 (1.9%)	
Children 5-17								
None	996 (53.4%)	698 (51.8%)	298 (57.4%)	0.02	1,935 (83.9%)	1,819 (84.6%	116 (74.8%	0.004
One	379 (20.3%)	271 (20.1%)	108 (20.8%)		201 (8.7%)	182 (8.5%)	19 (12.3%)	
Two or more	464 (24.9%)	357 (26.5%)	107 (20.6%)		121 (5.2%)	105 (4.9%)	16 (10.3%)	
Missing	27 (1.4%)	21 (1.6%)	6 (1.2%)		48 (2.1%)	44 (2.0%)	4 (2.6%)	
Chronic Health Conditions								
None	1,026 (55.0%)	776 (57.6%)	250 (48.2%)	0.0003	998 (43.3%)	944 (43.9%)	54 (34.8%)	0.029
One or more	839 (45.0%)	570 (42.3%)	269 (51.8%)		1,300 (56.4%)	1,199 (55.8%	101 (65.2%	
Missing	1 (0.1%)	1 (0.1%)	0 (0.0%)		7 (0.3%)	7 (0.3%)	0 (0.0%)	
Crisis score phase 1								
Mean (SD)	27.8 (±8.0)	26.6 (±7.7)	30.9 (±8.0)	< 0.0001	24.9 (±7.6)	24.6 (±7.4)	28.9 (±8.8)	< 0.0001
Missing	63 (3.4%)	51 (3.8%)	12 (2.3%)		86 (3.7%)	78 (3.6%)	8 (5.2%)	
Anxiety GAD-7 phase 1								
Mean (SD)	6.9 (±5.2)	6.2 (±4.9)	8.7 (±5.5)	< 0.0001	5.0 (±4.7)	4.8 (±4.6)	7.4 (±5.5)	< 0.0001
Missing	49 (2.6%)	40 (3.0%)	9 (1.7%)		106 (4.6%)	100 (4.7%)	6 (3.9%)	
Depression PHQ-9 phase 1								
Mean (SD)	6.5 (±5.2)	5.7 (±4.7)	8.6 (±5.9)	< 0.0001	5.0 (±4.5)	4.8 (±4.4)	7.8 (±5.7)	< 0.0001
Missing	61 (3.3%)	51 (3.8%)	10 (1.9%)		144 (6.2%)	134 (6.2%)	10 (6.5%)	

623
624
625

627 **Table 2.** Summary of free-text responses for changes noticed in menstrual cycles.
628 Sample sizes are given and percentages of total sample are given in parentheses.
629

Theme categories Total n = 92	Themes	Sub-themes	Participant response excerpts
Non-Pandemic related n = 29 (31.5)	**Age related** n = 15 (51.7)	**Entering perimenopause** n = 15 (51.7)	"I'm perimenopausal"; "perimenopausal, irregular, unpredictable"
	Changes to medication or contraceptives n = 6 (20.6)	**Changes to birth control (patch, pill, IUD)** n = 4 (13.7)	"Removed IUD so periods are balancing out"; "Started period after going off of birth control"
		Medication, supplements n = 2 (6.8)	"— I have recently stopped taking all those supplements and have noticed that my cycle in general is longer"; "Had a period when I had xxx, otherwise I haven't had a period in a while."
	Changes to reproductive system n = 8 (27.5)	**Got pregnant or intended to** n = 4 (13.7)	"I got pregnant in xx"; "Stopped due to positive pregnancy test"
		Hysterectomy n = 4 (13.7)	"Cycle starting to return after ablation"; "Had hysterectomy done in xx"
Pandemic control measures n = 63 (68.4)	**Cycle length/volume changes** n = 57 (90.4)	**Varying cycle timing (start/end)** n = 33 (52.3)	"Cycle is longer. Used to be 28 days. Now 31-32 days."; "My cycle is normally 28 days on average; in March it was 35 days, April 26 day, moving back to 30 days then 29."
		Changes in Period Length n = 14 (22.2)	"Irregular. Both long and short"; "Periods have become more irregular, sometimes long, sometimes short with some spotting in between"
		Volume changes (more or less bleeding) n = 10 (15.80)	"they are more variable… shorter, sometimes very light, other quite heavy and with more severe cramps"; "Short, long and light or heavy period. No idea what is happening sort of periods"
	Periods are more symptomatic n = 6 (9.5)	**Mood symptoms** n = 3 (4.7)	"More mood swings"; "Weird timing and more moody"
		Painful n = 3 (4.7)	"Extreme cramping throughout month of April"; "Worse migraines"

630
631

632 **Table 3.** Summary of free-text responses for changes noticed in postmenopausal
633 status. Sample sizes are given and percentages of total sample are given in
634 parentheses.
635

Theme categories Total n = 111	Themes	Sub-themes	Participant response excerpts
Non-pandemic related n = 22 (19.8)	**Surgery** n = 10 (45.4)	**Hysterectomy/Ovarian cysts** n = 10 (45.4)	
	Changes to medication n = 7 (31.8)	**Hormone replacement therapy (HRT) changes** n = 7 (31.8)	"My postmenopausal symptoms became more severe because of changes in HRT prescription."; " …tr(ied) a few replacement medications."
	Pre-existing conditions n = 5 (22.7)	**Endometriosis and cancer** n = 5 (22.7)	"I had endometrial biopsy xx procedure"; "Bleeding due to bladder cancer"
Pandemic control measures n = 89 (80.1)	**Menopause symptoms have worsened** n = 69 (77.5)	**Hot flashes and insomnia** n = 46 (51.6)	"Hot flashes- haven't had them in years."; "More insomnia and hot flashes, and painful dry eyes which I didn't have before."
		Mood symptoms n = 13 (14.6)	"Felt lonely and depressed and hopeless"; "More emotional and stronger symptoms"
		Vaginal dryness and skin irritation n = 7 (7.8)	"Vaginal dryness, painful sex, sweats"; "More skin irritation"
		Headaches/Migraines n = 2 (2.2)	"Migraine headaches, hot flashes"; "Headaches"
	Irregular changes to health n = 20 (22.4)	**Bleeding/abdominal pain** n = 9 (10.1)	"One episode of postmenopausal bleeding"; Abdominal pain and cramps in middle lower area."
		Weight changes and hair loss n = 8 (8.9)	"Slower metabolism/weight gain in different areas of body"; "More Uti's"
		Memory loss n = 1 (1.1)	"Memory is getting bad…feeling for words often."; "I have felt more symptoms such as brain fog and hot flashes which I assume are hormone related."

636
637
638

Figure 1 Changes to menstrual and menopausal status during early COVID-19
pandemic increased mean CoRonavIruS Health Impact survey (CRISIS) scores, anxiety
(GAD-7) and depression symptoms (PHQ-9) in women+. A) Mean (±95%CI) CRISIS
scores in women+ with changes to menstrual status were 3.4 points higher. B) Mean
(±95%CI) GAD-7 scores in women+ with changes to menstrual status were 2 points
higher. C) Mean (±95%CI) PHQ-9 scores in women+ with changes to menstrual status
were 2.4 D) Mean(±95%CI) CRISIS scores in women+ with changes to menopausal
status were 2.9 points higher. E) Mean (±95%CI) GAD-7 scores in women+ with
changes to menopausal status were 1.5 points higher. F) Mean(±95%CI) PHQ-9 scores
in women+ with changes to menopausal status were 1.8 points higher. CI=confidence
interval. Figure was constructed in R v.4.1.3.

<center>Supplement</center>

1. Are you postmenopausal (have not had a period in 1 year or more)?

● Yes

● No

2. [If "No" to question 1] Since the COVID-19 pandemic and subsequent public

health measures in mid-March 2020, have you noticed any changes to your

menstrual cycle?

● Yes

● No

● Not applicable: I have a suppressed menstrual cycle due to hormonal

contraception, breast feeding, a medical condition, etc.

● Not applicable: other

3. [If "yes" to question 2] What changes have you noticed to your menstrual cycle?

● Periods have gotten shorter

● Periods have gotten longer

● Periods are more symptomatic (painful, more bleeding, etc.)

● Periods are less symptomatic

● More periods than normal

● Fewer periods than normal

● Other

4. [If "other" to question 3] What other changes in your menstrual cycle have you

noticed since COVID-19?

5. [If "yes" to question 1] Have you noticed any changes to your postmenopausal

status since mid-March 2020?

● Yes

● No

6. [If "yes" to question 5] What changes have you noticed?

● Started bleeding again

● More menstrual symptoms

● Other

7. [If "other" to question 6] Please specify the "Other" changes you have

experienced in your postmenopausal status